Company Filing History:
Years Active: 2015-2023
Title: Claudia Nardini: Innovator in Plasma Protein Purification
Introduction
Claudia Nardini is a prominent inventor based in Lucca, Italy. She has made significant contributions to the field of biochemistry, particularly in the purification of plasma proteins. With a total of 3 patents to her name, her work has the potential to impact therapeutic applications for human diseases.
Latest Patents
One of her latest patents is a process for plasminogen purification starting from human plasma. This invention outlines a method for producing human plasminogen, which includes steps such as virus inactivation using a solvent/detergent mixture, a single affinity chromatographic step, and a virus removal nanofiltration step. This scalable process ensures a functional and intact finished product suitable for treating genetic plasminogen deficiency.
Another notable patent is for the highly selective purification of two plasma proteins: von Willebrand factor (vWF) and fibronectin (Fn). This chromatographic purification process allows for the extraction of highly purified vWF and Fn from a biological fraction enriched in these proteins. The method utilizes a strong anionic exchange resin, resulting in concentrates with high specific activity and low contaminant protein content, making them particularly suitable for therapeutic use.
Career Highlights
Claudia Nardini is currently associated with Kedrion S.p.a., a company known for its expertise in the production of plasma-derived therapies. Her innovative approaches in protein purification have positioned her as a key figure in the biopharmaceutical industry.
Collaborations
Claudia has collaborated with notable colleagues, including Claudio Farina and Alessandra Lazzarotti. These partnerships have further enhanced her research and development efforts in the field of plasma protein purification.
Conclusion
Claudia Nardini's contributions to the purification of plasma proteins demonstrate her commitment to advancing medical science. Her innovative patents have the potential to improve treatment options for patients with genetic deficiencies.